Endo, Novartis begin Voltaren gel licensing deal

Share this article:
Endo Pharmaceuticals has entered into a licensing agreement with Novartis to obtain the exclusive US marketing rights for the prescription medicine Voltaren Gel (diclofenac sodium topical gel) 1%.

Endo said it expects to commercialize Voltaren Gel initially using one of its two specialty sales forces, consisting of 160 reps, prior to executing a full physician launch in late May, with an additional 275 contract sales representatives targeting primary care physicians who prescribe NSAIDs and Cox-2s.
Voltaren Gel received FDA approval in October 2007, being granted marketing exclusivity in the US as a prescription medicine at least until October 2010.

Endo estimates US peak annual sales for Voltaren Gel as an osteoarthritis pain treatment in the range of $250-300 million.

Under the terms of the five-year agreement with Novartis, Endo will make an upfront cash payment of $85 million.

Novartis is also eligible to receive a one-time milestone payment of $25 million if annual sales exceed $300 million. Under the deal, Novartis will receive royalties on the net sales of Voltaren Gel in the US and will supply this product to Endo.
Share this article:
You must be a registered member of MMM to post a comment.

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...